Citation

Bogoslovsky T, Gill J, Jeromin A, Davis C, Diaz-Arrastia R. Diagnostics (Basel) 2016; 6(4): ePub.

Affiliation

Director, Traumatic Brain Injury Clinical Research Center, Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. ramondia@mail.med.upenn.edu.

Copyright

(Copyright © 2016, MDPI: Multidisciplinary Digital Publishing Institute)

DOI

10.3390/diagnostics6040037

PMID

27763536

Abstract

Traumatic brain injury (TBI) is one of the leading causes of death and disability around the world. The lack of validated biomarkers for TBI is a major impediment to developing effective therapies and improving clinical practice, as well as stimulating much work in this area. In this review, we focus on different settings of TBI management where blood or cerebrospinal fluid (CSF) biomarkers could be utilized for predicting clinically-relevant consequences and guiding management decisions. Requirements that the biomarker must fulfill differ based on the intended context of use (CoU). Specifically, we focus on fluid biomarkers in order to: (1) identify patients who may require acute neuroimaging (cranial computerized tomography (CT) or magnetic resonance imaging (MRI); (2) select patients at risk for secondary brain injury processes; (3) aid in counseling patients about their symptoms at discharge; (4) identify patients at risk for developing postconcussive syndrome (PCS), posttraumatic epilepsy (PTE) or chronic traumatic encephalopathy (CTE); (5) predict outcomes with respect to poor or good recovery; (6) inform counseling as to return to work (RTW) or to play. Despite significant advances already made from biomarker-based studies of TBI, there is an immediate need for further large-scale studies focused on identifying and innovating sensitive and reliable TBI biomarkers. These studies should be designed with the intended CoU in mind.

Language: en